TY - JOUR
T1 - Gene therapy approaches for the management of non-small cell lung cancer
AU - Roth, Jack A.
AU - Grammer, Susan F.
AU - Swisher, Stephen G.
AU - Komaki, Ritsuko
AU - Nemunaitis, John
AU - Merritt, James
AU - Fujiwara, Toshiyoshi
AU - Meyn, Raymond E.
N1 - Funding Information:
Supported by grants from the National Cancer Institute and the National Institutes of Health (PO1 CA787780OlA1); by a grant for a Specialized Program of Research Excellence in Lung Cancer (P50CA70907); the W.M. Keck Foundation, by gifts to the Division of Surgery and Anesthesiology from Tenneco and Exxon for the Core Laboratory Facility; by The University of Texas M. D. Anderson Cancer Center Support Core Grunt (CA1 6672); and by a sponsored research agreement with Introgen Therapeutics, Inc.
Funding Information:
Dr Roth has sewed as a consultant to and has received research grant support from lntrogen Therapeutics, Inc. Dr Swisher has received research grant support from Introgen Therapeutics, Inc and Auentis. Dr Merritt is an employee of Introgen Therapeutics, Inc. Dr Fuji-wara serves as a consultant to Introgen Therapeutics, Inc. Dr Meyn has receiered research grant support from Introgen Therapeutics, Inc.
PY - 2001
Y1 - 2001
N2 - Targeting the specific genetic lesions responsible for carcinogenesis and cancer progression is an attractive strategy for developing more effective anticancer therapies and reducing treatment-related toxicity. The restoration of defective tumor suppressor gene pathways by replacement of tumor suppressor genes in cancer cells has been studied in lung cancer. The most extensively studied agent is the wild-type p53 tumor suppressor gene delivered by an adenoviral vector. Clinical trials to date in non-small cell lung cancer and head and neck cancer have consistently shown evidence of gene transduction and expression, mediation of apoptosis, and clinical responses including pathologic complete responses. However, it also is clear that this approach can be improved. Promising avenues for investigation include improved gene delivery systems, induction of bystander effects, and adjuvant use of gene therapy with conventional chemotherapy, radiation therapy, and surgery. However, these strategies will need further refinement to succeed clinically. This review examines several important issues in cancer gene therapy in general and the most recent achievements in gene therapy for non-small cell lung cancer.
AB - Targeting the specific genetic lesions responsible for carcinogenesis and cancer progression is an attractive strategy for developing more effective anticancer therapies and reducing treatment-related toxicity. The restoration of defective tumor suppressor gene pathways by replacement of tumor suppressor genes in cancer cells has been studied in lung cancer. The most extensively studied agent is the wild-type p53 tumor suppressor gene delivered by an adenoviral vector. Clinical trials to date in non-small cell lung cancer and head and neck cancer have consistently shown evidence of gene transduction and expression, mediation of apoptosis, and clinical responses including pathologic complete responses. However, it also is clear that this approach can be improved. Promising avenues for investigation include improved gene delivery systems, induction of bystander effects, and adjuvant use of gene therapy with conventional chemotherapy, radiation therapy, and surgery. However, these strategies will need further refinement to succeed clinically. This review examines several important issues in cancer gene therapy in general and the most recent achievements in gene therapy for non-small cell lung cancer.
UR - http://www.scopus.com/inward/record.url?scp=0034786857&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034786857&partnerID=8YFLogxK
U2 - 10.1053/sonc.2001.27636
DO - 10.1053/sonc.2001.27636
M3 - Review article
C2 - 11605184
AN - SCOPUS:0034786857
VL - 28
SP - 50
EP - 56
JO - Seminars in Oncology
JF - Seminars in Oncology
SN - 0093-7754
IS - 4 SUPPL. 14
ER -